Slideshow

The Artificial Sweetener Paradox: Weight Gain and Metabolic Dysfunction?

A new meta-analysis finds that routine intake of artificial sweeteners is linked to the opposite of the intended effect.

The Academy of Nutrition and Dietetics' current position on nonnutritive sweeteners is that they may help limit inatke of energy in an effort to manage weight or blood glucose. The consumption of artificial sweeteners, including aspartame, sucralose, and stevia, however, has been associated with both weight gain and incident obesity. Existing evidence, from both randomized controlled trials and observational studies, is conflicting.The objective of the meta-analysis summarized in the short slide show above was to determine whether "routine consumption of nonnutritive sweeteners by adults and adolescents [is] associated with adverse long-term cardiometabolic effects in RCTs and prospective cohort studies."

References:

1. Swithers SE. Artificial sweeteners produce the counterintuitive effect of inducing metabolic derangements. Trends Endocrinol Metab. 2013;24:431–41.

2. Nettleton JE, Reimer RA, Shearer J. Reshaping the gut microbiota: Impact of low calorie sweeteners and the link to insulin resistance? Physiol Behav. 2016; 164(Pt B):488–93

3. Azad MB, Abou-Setta AM, Chauhan BF, et al. Nonnutritive sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. CMAJ. 2017;189:E929-E939. doi: 10.1503/cmaj.161390.

Related Videos
The APAC Recap: Cardiomyopathy at CAPP Live 2024 with Greg Duck, PA-C | Image Credit: APAC
The APAC Recap: Peripheral Artery Disease at CAPP Live 2024 with Bob Ross, PA-C | Image Credit: APAC
AMG0001 Advances Healing in CLTI with David G. Armstrong, DPM, PhD, and Michael S. Conte, MD | Image Credit: Canva
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
© 2024 MJH Life Sciences

All rights reserved.